Advertisement

Topics

Merck Begins Two Phase 3 Studies Of Pneumococcal Disease Vaccine PCV-15 (V114)

08:48 EDT 17 Apr 2018 | RTTNews

Merck & Co. Inc. (MRK) said it is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

Original Article: Merck Begins Two Phase 3 Studies Of Pneumococcal Disease Vaccine PCV-15 (V114)

NEXT ARTICLE

More From BioPortfolio on "Merck Begins Two Phase 3 Studies Of Pneumococcal Disease Vaccine PCV-15 (V114)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...